Hanadie Yousef, CEO of Juvena Therapeutics, is one of In Vivo's 2024 Rising Leaders. She co-founded Juvena based on the science of the secretome, the collection of proteins secreted by human stem cells. In this episode, Yousef explains the science behind the secretome, Juvena's platform, the company's lead assets and her experience as a young entrepreneur.
Podcast: The Secretome, Longevity Medicine And Alternatives To GLP-1 Agonists
Podcast: In Conversation With 2024 Rising Leader, Hanadie Yousef
One of In Vivo's 2024 Rising Leaders, Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company's lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.
More from Rising Leaders
• By
It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.
• By
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
• By
Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech.
• By
“I'm a strong believer in creating the right mix between young ambitious people and pairing them up with someone experienced,” says Jeroen Bakker, who is focused on biotech company creation at Seed Investments, Novo Holdings.
More from Leadership
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.